[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adrenalectomy-status\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adrenalectomy-status":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,73,99],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100637013","phase-2-tirzepatide-following-adrenalectomy-in-mild-autonomous-cortisol-secretion-100637013",false,"NCT07573163","Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion","A Randomized Clinical Trial of Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion","Inclusion Criteria:\n\n* Adults aged 18 years and older\n* Diagnosis of MACS, defined as morning cortisol \\>1.8 mcg\u002FdL after a 1 mg dexamethasone suppression test\n* Elevated blood pressure (SBP ≥120 mmHg or DBP ≥80 mmHg per the 2025 American College of Cardiology\u002FAmerican Heart Association \\[ACC\u002FAHA\\] criteria, or current use of antihypertensive medication)\n* BMI ≥27\n* Undergoing or having undergone adrenalectomy for the treatment of MACS\n\nExclusion Criteria:\n\n* Bilateral adrenal lesions\n* Adrenal malignancy\n* Concurrent primary aldosteronism with MACS\n* Current use of GLP-1 receptor agonists\n* Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)\n* Pregnancy or breastfeeding","ALL","18 Years",{"count":19,"type":20},34,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Mild Autonomous Cortisol Secretion (MACS) is a condition in which an adrenal gland produces excess cortisol and is associated with high blood pressure, diabetes, and weight gain. Surgical removal of the adrenal gland (adrenalectomy) is standard treatment, but some patients continue to have metabolic health problems after surgery.\n\nThis randomized study will evaluate whether treatment with tirzepatide after adrenalectomy improves metabolic outcomes in patients with MACS compared with adrenalectomy alone.",[26,27],"Mild Autonomous Cortisol Secretion (MACS)","Adrenalectomy; Status",[29,30,31],"adrenalectomy","MACS","mild autonomous cortisol secretion","NOT_YET_RECRUITING","2026-06-29",{"date":35,"type":36},"2026-07-01","ACTUAL",{"date":38,"type":20},"2026-07",{"date":40,"type":20},"2028-12-31",{"name":42,"class":43},"Alaa Sada","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":44},"100493268","phase-4-the-effect-and-safety-of-omitting-preoperative-alpha-adrenergic-blockade-for-normotensive-pheochromocytoma-100493268","NCT05702944","The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma","A Pilot Study for Randomized Controlled Trial on the Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma","Inclusion Criteria:\n\n* Patients aged 19 to 70 years old\n* Patients who consented to the study and obtained consent for the study\n* Patients undergoing unilateral total adrenalectomy due to normotensive pheochromocytoma\u002Fparaganglioma with less than five times of upper limits of serum metanephrine\n\nExclusion Criteria:\n\n* Patients under 18 or over 70 years old\n* Pregnant women\n* Patients with bilateral pheochromocytoma\n* Patients suspected of malignant pheochromocytoma\u002Fparaganglioma or distant metastasis\n* Patients requiring preoperative intensive care unit due to severe hemodynamic instability\n* Patients with hypertension (the blood pressure measured more than two times is constantly greater than 140\u002F90 mmHg) or already taking a antihypertensive medication\n* Patients with a history of coronary artery disease\n* Patients with a history of arrhythmia (atrial fibrillation, Paroxysmal supraventricular tachycardia)\n* Patients with a history of cerebrovascular disease (cerebral aneurysm, cerebral infarction, cerebral hemorrhage)\n* Patients judged unsuitable by the person in charge of the clinical trial","19 Years","70 Years",{"count":55,"type":20},24,[57],"PHASE4","Pheochromocytoma and paraganglioma (PPGL) are rare neuroendocrine tumors originating from catecholamine producing chromaffin cells in the adrenal medulla and extra-adrenal paraganglia. The overall age-standardized incidence rate is 0.18 per 100,000 person-years in Korea.\n\nThe definitive treatment of PPGL is surgical excision of tumor. However, surgery is associated with a high risk of perioperative hemodynamic instability (HI). To avoid perioperative HI in patients diagnosed with PPGL, preoperative management including routine use of alpha blockade and volume expansion has been advocated by several guidelines.\n\nWhile unstable hypertension and tachycardia should be controlled in patients with PPGL, there is controversial that all patients diagnosed with PPGL should undergo preoperative pharmacological treatment, especially alpha blockade. The most important risk of preoperative alpha blockade use is perioperative hypotension.\n\nA recent study reported that patients diagnosed with PPGL postoperatively may have no further higher risk of intraoperative hypertension than those diagnosed preoperatively despite insufficient preoperatively management of PPGL.\n\nTherefore, it is a very important to study the relationship between HI and preoperative alpha blockade in normotensive patients diagnosed with PPGL. The aim this study is to analyze the effect and safety of omitting preoperative alpha-adrenergic blockade for normotensive pheochromocytoma through a prospective randomized controlled trial. The patients is divided into two groups. The patients in control group take a phenoxybenzamine at least 2 to 5 weeks before surgery. The patients in case group do not take a phenoxybenzamine.\n\nPrimary outcome is to evaluate the percentage of time during surgery with systolic blood pressure more than 160mmHg or average blood pressure less than 60mmHg. And secondary outcomes are to evaluate hemodynamic instability in preoperative ward and postoperative ward.",[60,61,27,62],"Pheochromocytoma","Paraganglioma","Adrenergics Causing Adverse Effects in Therapeutic Use","RECRUITING","2025-06-09",{"date":66,"type":36},"2025-06-12",{"date":68,"type":36},"2023-01-18",{"date":70,"type":20},"2027-12-31",{"name":72,"class":43},"Seoul National University Hospital",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":44},"100432022","3d-laparoscopic-adrenalectomies-for-adrenal-tumors-100432022","NCT04905706","3D Laparoscopic Adrenalectomies for Adrenal Tumors","Three-dimensional Laparoscopic Adrenalectomies for Benign and Malignant Adrenal Tumors","Inclusion Criteria:\n\n* All adult patients (age ≥ 18 years)\n* Patients diagnosed with adrenal masses (benign and malignant tumors)\n* Underwent a unilateral 3D laparoscopic adrenalectomy from January 2013 to December 2033.\n\nExclusion Criteria:\n\n* Emergency surgery.\n* Open adrenalectomy.\n* Bilateral adrenalectomies (open or laparoscopy).\n* Patients who underwent laparoscopic adrenalectomy together with another laparoscopic surgical procedure in the same intervention.\n* Patients without complete follow-up for at least 30 days after hospital discharge.",{"count":81,"type":20},300,"OBSERVATIONAL","The main drawbacks of conventional 2D laparoscopy are limited depth perception and loss of spatial orientation. High-quality 3D laparoscopy systems might improve surgical outcomes for adrenalectomy.",[85,27],"Adrenal Tumor",[87,88,89],"Three-dimensional laparoscopy","Adrenal tumors","3D laparoscopic adrenalectomy","2025-05-06",{"date":92,"type":36},"2025-05-09",{"date":94,"type":36},"2013-01-01",{"date":96,"type":20},"2033-12-31",{"name":98,"class":43},"Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":108,"conditions":109,"keywords":120,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":44},"100519938","surgical-treatment-of-adrenal-diseases--laparoscopic-vs-robotic-assisted-adrenalectomy-100519938","NCT06050057","Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy","Possibilities of Surgical Treatment of Adrenal Diseases: Comparison of Laparoscopic and Robotic-assisted Adrenalectomy-a Prospective Study","Inclusion Criteria:\n\n* Indicated adrenalectomy based on endocrinological and imaging examination.\n* Written consent to participate in the study.\n\nExclusion Criteria:\n\n* Simultaneous bilateral adrenalectomy.\n* Adrenal expansion \\> 12 cm.\n* Suspected malignant adrenal tumor with infiltrative growth or tumor venous thrombus according to imaging examination.",{"count":107,"type":20},100,"The goal of this multicenter, observational, analytic, randomized clinical trial is to analyze the laparoscopic and robot-assisted method in the surgical treatment of patients with adrenal diseases. The main question it aims to answer are:\n\n1. to find the superiority of one the the surgical method mentioned above\n2. to compare the quality of life in patients with adrenal mass before surgery and after laparoscopic or robotic-assisted adrenalectomy.",[85,110,111,27,112,113,114,60,115,116,117,118,119],"Adrenal Disease","Adrenal Mass","Adrenal Hyperplasia","Adrenal Gland Metastasis","Adrenal Cortex Diseases","Cushing Syndrome","Conn Adenoma","Adrenocortical Carcinoma","Adrenocortical Adenoma","Adrenocortical Tumor",[85,60,116,115,121,122,123],"Adrenalectomy","Laparoscopic surgery","da Vinci surgical system","2023-09-17",{"date":126,"type":36},"2023-09-22",{"date":128,"type":36},"2023-09-03",{"date":130,"type":20},"2026-06-30",{"name":132,"class":43},"University Hospital Olomouc"]